Tolerance and chimerism

Transplantation

Volumn 75, Issue 9 SUPPL., 2003, Pages

  Kolb, Hans Jochem ^a,b   Guenther, Wolfgang ^a,b   Gyurkocza, Boglarka ^a,b   Hoetzl, Florian ^a,b   Simoes, Belinda ^a,b   Falk, Christine ^a,b   Schleuning, Michael ^a,b   Ledderose, Georg ^a,b  

^a UNIVERSITY OF MUNICH   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD6 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; HLA ANTIGEN; LEUKOCYTE ANTIGEN; LYMPHOCYTE ANTIBODY; MESNA; METHOTREXATE; THYMOCYTE ANTIBODY;

BONE MARROW PURGING; CHIMERA; CLINICAL TRIAL; CONFERENCE PAPER; DOG; DRUG EFFECT; DRUG EFFICACY; EXPERIMENTAL MODEL; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HAPLOIDY; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC SYSTEM TUMOR; HISTOINCOMPATIBILITY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; LEUKEMIA; LYMPHOCYTE DEPLETION; LYMPHOMA; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; STEM CELL MOBILIZATION; STEM CELL TRANSPLANTATION; SURVIVAL; T LYMPHOCYTE; WHOLE BODY RADIATION;

ANIMALS; BLOOD GROUP INCOMPATIBILITY; CYCLOPHOSPHAMIDE; DOGS; GRAFT VS HOST DISEASE; HUMANS; LEUKEMIA; STEM CELL TRANSPLANTATION; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION TOLERANCE; WHOLE-BODY IRRADIATION;

EID: 0037955569     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (33)

1. Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998; 339: 1186-1193.
2. Guinan EC, Boussiotis VA, Neuberg D, et al. Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med 1999; 340: 1704-1714.
3. Sykes M, Preffer F, McAfee S, et al. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet 1999; 353: 1755-1759.
4. Deeg HJ, Raff RF, Grosse-Wilde H, et al. Joint report of the Third International Workshop on Canine Immunogenetics: I. Analysis of homozygous typing cells. Transplantation 1986; 41: 111-117.
5. Grosse-Wilde H, Vriesendorp HM, Wank R, et al. Identification of four MLC-specificities in the dog. Tissue Antigens 1974; 4: 229-237.
6. Rieder I, Kolb HJ, Schäffer E, et al. Leukocyte transfusions for modification of host-versus-graft reactions in dogs. In: Baum SJ, Ledney GD, eds. Experimental hematology today. Heidelberg, Springer 1978, pp 101-107.
7. Berenbaum MC. Effect of cyclophosphamide on the homograft response in the guinea pig. Transplantation 1965; 3: 671-673.
8. Kernan NA, Collins NJ, Juliano L, et al. Clonable T-lymphocytes in T-depleted bone marrow transplants correlate with development of graftversus-host disease. Blood 1986; 68: 770.
9. Kolb HJ, Losslein LK, Beisser K, et al. Dose rate and fractionation of total body irradiation in dogs: Short and long term effects. Radiother Oncol 1990; 18(suppl 1): 51-59.
10. Shank B, O'Reilly RJ, Cunningham I, et al. Total body irradiation for bone marrow transplantation: The Memorial Sloan-Kettering Cancer Center experience. Radiother Oncol 1990; 18(suppl 1): 68-81.
11. Losslein LK, Kolb HJ, Porzsolt S, et al. Hyperfractionation of total-body irradiation and engraftment of marrow from DLA-haploidentical littermates. Transplant Proc 1987; 19: 2707-2708.
12. Storb R, Kolb HJ, Deeg HJ, et al. Prevention of graft-versus-host disease by immunosuppressive agents after transplantation of DLA-nonidentical canine marrow. Bone Marrow Transplant 1986; 1: 167-177.
13. Thierfelder S, Rodriguez-Paradisi E, Mempel W, et al. Cytology and histology of haemopoietic cell transplantation under the influence of ALS in mice: II. The effect of marrow from donors pretreated with antilymphocyte serum (ALS) on the recipient. Clin Exp Immunol 1971; 8: 121-129.
14. Kolb HJ, Rieder I, Rodt H, et al. Antilymphocytic antibodies and marrow transplantation: VI. Graft-versus-host tolerance in DLA-incompatible dogs after in vitro treatment of bone marrow with absorbed antithymocyte globulin. Transplantation 1979; 27: 242-245.
15. Kolb HJ, Bodenberger U, Rodt HV, et al. Bone marrow transplantation in DLA-haploidentical canine littermates: Fractionated total body irradiation (FTBI) and in vitro treatment of the marrow graft with anti-T-cell globulin (ATCG). Hamatol Bluttransfus 1980; 25: 61-71.
16. Mysliwietz J, Hoffmann Fezer G, Thierfelder S, et al. Recognition of two epitopes of an antigen present on canine T cells but not on hemopoietic progenitors by four monoclonal antibodies. Transplantation 1988; 45: 443-448.
17. Schumm M, Günther W, Kolb HJ, et al. Prevention of graft-versus-host disease in DLA-haplotype mismatched dogs and hemopoietic engraftment of CD6-depleted marrow with and without cG-CSF treatment after transplantation. Tissue Antigens 1994; 43: 170-178.
18. Guenther W, Schumm M, Buettner M, et al. NK activity of canine blood and marrow cells. Tissue Antigens 1994; 34: 198-201.
19. Thomas ED, Storb R, Cliff RA, et al. Bone marrow transplantation. N Engl J Med 1975; 292: 832-843.
20. Ash RC, Horowitz MM, Gale RP, et al. Bone marrow transplantation from related donors other than HLA-identical siblings: Effect of T cell depletion. Bone Marrow Transplant 1991; 7: 443-452.
21. Anasetti C, Amos D, Beatty PG, et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med 1989; 320: 197-204.
22. Kaufman CL, Colson YL, Wren SM, et al. Phenotypic characterization of a novel bone-marrow derived cell that facilitates engraftment of allogeneic bone marrow stem cells. Blood 1994; 84: 2436-2440.
23. Neipp M, Zorina T, Domenick MA, et al. Effect of FLT3 ligand and granulocyte colony stimulating factor on expansion and mobilization of facilitating cells and hematopoietic stem cells in mice: Kinetics and repopulating potential. Blood 1998; 92: 3177-3188.
24. Gandy KL, Domen J, Aguila H, et al. CD8+TCR+ and CD8+TCR-cells in whole bone marrow facilitate the engraftment of hematopoietic stem cells across allogeneic barriers. Immunity 1999; 11: 579-590.
25. Reisner Y, Martelli MF. Transplantation tolerance induced by "mega dose" CD34+ cell transplants. Exp Hematol 2000; 28: 119-127.
26. Reich-Zeliger S, Zhao Y, Krauthgamer R, et al. Anti-third party CD8+ CTLs as potent veto cells: Coexpression of CD8 and FasL is a prerequisite. Immunity 2000; 13: 507-515.
27. Lan F, Zeng D, Huie P, et al. Allogeneic bone marrow cells that facilitate complete chimerism and eliminate tumor cells express both CD8 and T-cell antigen receptor-αβ. Blood 2001; 97: 3458-3465.
28. Schuchert MJ, Wright RD, Colson YL. Characterization of a newly discovered T-cell receptor β-chain heterodimer expressed on CD8-positive bone marrow subpopulation that promotes allogeneic stem cell engraftment. Nat Med 2000; 6: 904-909.
29. Reinherz EL, Geha R, Rappeport JM, et al. Reconstitution after transplantation with T-lymphocyte-depleted HLA haplotype-mismatched bone marrow for severe combined immune deficiency. Proc Natl Acad Sci USA 1982; 79: 6047-6051.
30. Soiffer R, Murray C, Cochran K, et al. Clinical and immunological effects of prolonged infusions of low dose recombinant interleukin-2 after autologous and T-cell depleted allogeneic bone marrow transplantation. Blood 1992; 79: 517.
31. Singer NG, Fox DA, Haqqi TM, et al. CD6: Expression during development, apoptosis and selection of human and mouse thymocytes. Int Immunol 2002; 14: 585-597.
32. van Kempen LCLT, Nelissen JMDT, Degen WGJ, et al. Molecular basis for the homophilic activated leukocyte cell adhesion molecule (ALCAM)-ALCAM interaction. J Biol Chem 2001; 276: 25783-25790.
33. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097-2100.